Detectability of Cytokine and Chemokine using ELISA, following Sample-inactivation using Triton X-100 or Heat
Author:
Labossiere Erica Hofer1, Gonzalez-Diaz Sandra1, Enns Stephanie2, Lopez Paul1, Yang Xuefen1, Kidane Biniam2, Vazquez-Grande Gloria3, Siddik Abu Bakar1, Kung Sam Kam-Pun4, Sandstrom Paul1, Ravandi Amir5, Ball T. Blake1, Su Ruey-Chyi1
Affiliation:
1. JC WILT Infectious Disease Research Center, National Microbiology Laboratories, Public Health Agency of Canada 2. Section of Thoracic Surgery, Dept. of Surgery, and Department of Biomedical Engineering, Price Faculty of EngineeringHealth Sciences Centre, University of Manitoba 3. Section of Critical Care Medicine, University of Manitoba 4. Dept. Immunology, University of Manitoba 5. Cardiovascular Lipidomics, Institute of Cardiovascular Sciences, St. Boniface Hospital, Max Rady College of Medicine, University of Manitoba
Abstract
Abstract
Background
Routine characterization of clinical samples for their immunological responses against infectious pathogens often involves assessing cytokine/chemokine profiles and/or production of pathogen-specific antibodies. To prevent transmission of infectious materials in laboratories, these clinical samples are often inactivated by detergents or heat before the molecular assays are performed. Antibody-based molecular assays, such as ELISA, are highly sensitive to conformational changes in analytes. How specific inactivation procedures impact on cytokine/chemokine detectability in the clinical samples is not fully elucidated. This study compared two commonly used inactivation methods (Triton X-100, heat-inactivation) and untreated native samples in the cytokine/chemokine assays.
Method
Plasma, endotracheal tube aspirate (ETTA), and nasopharyngeal (NP) samples underwent inactivation with 0.05% Triton X-100 or heat (60°C, 1 hour). Cytokines/chemokine levels were assessed using Meso-Scale-Multi-Spot assays. Data were analyzed against untreated samples using one-way and Tukey’s multiple comparisons tests. Additionally, the conformational instability of cytokines/chemokines, predicted by their amino acid sequence, was examined to determine its contribution to detectability in inactivated samples.
Results
Heat treatment significantly impacted cytokine/chemokine detection across sample types. IL-1α levels were substantially reduced in ETTA, NP, and plasma samples. In heat-inactivated plasma, IL-12p40, IL-15, IL-16, VEGF, IL-7, and TNF-β, among 36 cytokines, were reduced by 33-99% (p-values ≤0.02). Conversely, Triton X-100 minimally affected cytokine/chemokine detection in plasma and NP samples by 11-37% (p-values ≤0.04). Triton X-100 increased the detection of IL-15, IL-16, IL-1α, VEGF, and IL-7 levels in NP samples. Triton X-100-inactivated ETTA samples showed no significant impact on cytokine/chemokine detectability. Heat inactivation had more profound impacts on protein detectability. Structural analysis revealed heat-affected cytokines had more hydrophobic residues and higher instability indices, although protein features alone could not reliably predict susceptibility.
Conclusion
Our findings demonstrated the importance of empirical assessments of inactivation protocols in the measurements of cytokine/chemokine responses in clinical samples. Overall, Triton X-100 performed better than heat inactivation in preserving protein conformation for antibodies-based immunological studies.
Publisher
Research Square Platform LLC
Reference44 articles.
1. Roles in leukocyte development, trafficking, and effector function;Ono SJ;J Allergy Clin Immunol,2003 2. Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation;Xie JH;J Leukoc Biol,2003 3. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (1979). 2021;371(6529). 4. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology;Channappanavar R;Semin Immunopathol,2017 5. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19);Wiersinga WJ;JAMA,2020
|
|